FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387396510> ?p ?o ?g. }

• W4387396510 abstract "PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability to understand patient toxicity burden. We analyze the relationship between the grades of AEs experienced with patient side-effect bother and treatment discontinuation. METHODS We analyzed a phase III Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial with comprehensive AE data. The Likert response Functional Assessment of Cancer Therapy-GP5 item, “I am bothered by side effects of treatment” was used to define side-effect bother. Bayesian mixed models were used to assess the impact of G1 and G2 AE counts on patient side-effect bother and treatment discontinuation. AEs were further analyzed on the basis of symptomatology (symptomatic or asymptomatic). The results are given as odds ratios (ORs) and 95% credible interval (CrI). RESULTS Each additional G1 and G2 AEs experienced during a treatment cycle increased the odds of increased self-reported patient side-effect bother by 13% (95% CrI, 1.06 to 1.21) and 35% (95% CrI, 1.19 to 1.54), respectively. Furthermore, only AEs defined as symptomatic were associated with increased side-effect bother, with asymptomatic AEs showing no association regardless of grade. Count of G2 AEs increased the odds of treatment discontinuation by 59% (95% CrI, 1.32 to 1.95), with symptomatic G2 AEs showing a stronger association (OR, 1.75; 95% CrI, 1.28 to 2.39) relative to asymptomatic G2 AEs (OR, 1.45; 95% CrI, 1.12 to 1.89). CONCLUSION Low- and moderate-grade AEs are related to increased odds of increased patient side-effect bother and treatment discontinuation, with symptomatic AEs demonstrating greater magnitude of association than asymptomatic. Our findings suggest that limiting AE capture to grade 3+ misses important contributors to treatment side-effect bother and discontinuation." @default.
• W4387396510 created "2023-10-07" @default.
• W4387396510 creator A5014494071 @default.
• W4387396510 creator A5015973900 @default.
• W4387396510 creator A5024795182 @default.
• W4387396510 creator A5028764986 @default.
• W4387396510 creator A5033825180 @default.
• W4387396510 creator A5037443640 @default.
• W4387396510 creator A5038425269 @default.
• W4387396510 creator A5039180386 @default.
• W4387396510 creator A5039323820 @default.
• W4387396510 creator A5041565579 @default.
• W4387396510 creator A5044564476 @default.
• W4387396510 creator A5051051055 @default.
• W4387396510 creator A5078129443 @default.
• W4387396510 creator A5085875361 @default.
• W4387396510 creator A5090301769 @default.
• W4387396510 creator A5090808981 @default.
• W4387396510 date "2023-10-06" @default.
• W4387396510 modified "2023-10-17" @default.
• W4387396510 title "Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial" @default.
• W4387396510 cites W2105258029 @default.
• W4387396510 cites W2105758667 @default.
• W4387396510 cites W2113464761 @default.
• W4387396510 cites W2157875025 @default.
• W4387396510 cites W2168278891 @default.
• W4387396510 cites W2314226163 @default.
• W4387396510 cites W2344407614 @default.
• W4387396510 cites W2749069611 @default.
• W4387396510 cites W2769746786 @default.
• W4387396510 cites W2786403629 @default.
• W4387396510 cites W2787929656 @default.
• W4387396510 cites W2962758893 @default.
• W4387396510 cites W2966190920 @default.
• W4387396510 cites W3007702378 @default.
• W4387396510 cites W3029407015 @default.
• W4387396510 cites W3132467283 @default.
• W4387396510 cites W3208295890 @default.
• W4387396510 cites W4205780663 @default.
• W4387396510 cites W4207055625 @default.
• W4387396510 cites W4311387150 @default.
• W4387396510 doi "https://doi.org/10.1200/jco.23.00377" @default.
• W4387396510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37801678" @default.
• W4387396510 hasPublicationYear "2023" @default.
• W4387396510 type Work @default.
• W4387396510 citedByCount "0" @default.
• W4387396510 crossrefType "journal-article" @default.
• W4387396510 hasAuthorship W4387396510A5014494071 @default.
• W4387396510 hasAuthorship W4387396510A5015973900 @default.
• W4387396510 hasAuthorship W4387396510A5024795182 @default.
• W4387396510 hasAuthorship W4387396510A5028764986 @default.
• W4387396510 hasAuthorship W4387396510A5033825180 @default.
• W4387396510 hasAuthorship W4387396510A5037443640 @default.
• W4387396510 hasAuthorship W4387396510A5038425269 @default.
• W4387396510 hasAuthorship W4387396510A5039180386 @default.
• W4387396510 hasAuthorship W4387396510A5039323820 @default.
• W4387396510 hasAuthorship W4387396510A5041565579 @default.
• W4387396510 hasAuthorship W4387396510A5044564476 @default.
• W4387396510 hasAuthorship W4387396510A5051051055 @default.
• W4387396510 hasAuthorship W4387396510A5078129443 @default.
• W4387396510 hasAuthorship W4387396510A5085875361 @default.
• W4387396510 hasAuthorship W4387396510A5090301769 @default.
• W4387396510 hasAuthorship W4387396510A5090808981 @default.
• W4387396510 hasConcept C126322002 @default.
• W4387396510 hasConcept C156957248 @default.
• W4387396510 hasConcept C160798450 @default.
• W4387396510 hasConcept C197934379 @default.
• W4387396510 hasConcept C199360897 @default.
• W4387396510 hasConcept C2777793932 @default.
• W4387396510 hasConcept C2777910003 @default.
• W4387396510 hasConcept C2778715236 @default.
• W4387396510 hasConcept C3454156 @default.
• W4387396510 hasConcept C41008148 @default.
• W4387396510 hasConcept C44249647 @default.
• W4387396510 hasConcept C71924100 @default.
• W4387396510 hasConceptScore W4387396510C126322002 @default.
• W4387396510 hasConceptScore W4387396510C156957248 @default.
• W4387396510 hasConceptScore W4387396510C160798450 @default.
• W4387396510 hasConceptScore W4387396510C197934379 @default.
• W4387396510 hasConceptScore W4387396510C199360897 @default.
• W4387396510 hasConceptScore W4387396510C2777793932 @default.
• W4387396510 hasConceptScore W4387396510C2777910003 @default.
• W4387396510 hasConceptScore W4387396510C2778715236 @default.
• W4387396510 hasConceptScore W4387396510C3454156 @default.
• W4387396510 hasConceptScore W4387396510C41008148 @default.
• W4387396510 hasConceptScore W4387396510C44249647 @default.
• W4387396510 hasConceptScore W4387396510C71924100 @default.
• W4387396510 hasLocation W43873965101 @default.
• W4387396510 hasLocation W43873965102 @default.
• W4387396510 hasOpenAccess W4387396510 @default.
• W4387396510 hasPrimaryLocation W43873965101 @default.
• W4387396510 hasRelatedWork W1601684588 @default.
• W4387396510 hasRelatedWork W1897313079 @default.
• W4387396510 hasRelatedWork W2104328188 @default.
• W4387396510 hasRelatedWork W2108427450 @default.
• W4387396510 hasRelatedWork W2360693916 @default.
• W4387396510 hasRelatedWork W2396330467 @default.
• W4387396510 hasRelatedWork W2915108716 @default.
• W4387396510 hasRelatedWork W4220795960 @default.
• W4387396510 hasRelatedWork W648938440 @default.

• next